1000257842.jpg
+2 more
Analyze this report explain this I want explain this case and also prognosis is this case
analyse_media
analyse_media
analyse_media
Reading File
Finding Sources
Finding Sources
Searching PubMed
"breast cancer" AND "PET-CT" AND "initial staging" AND "axillary lymph nodes"
Reading File
Reading File
I now have all the information needed to provide a thorough explanation. Here is the complete analysis:
Whole Body ¹⁸F-FDG PET-CT Report Analysis
Patient: Rita Ronad | Female | 56 years | Date: 4-Aug-2026
Reason for scan: Carcinoma of left breast - Initial Staging
Institution: Ashoka - Cancer Centers of America (CCA), Nashik
What Is This Scan?
A Whole Body FDG PET-CT is a nuclear medicine scan that combines:
- PET (Positron Emission Tomography): Detects metabolically active (cancer) cells by measuring glucose uptake using radioactive fluorine-18 labelled glucose (¹⁸F-FDG)
- CT (Computed Tomography): Provides anatomical/structural detail
Cancer cells consume glucose at a much higher rate than normal cells, so they "light up" on PET. The metric SUVmax (Standardized Uptake Value) measures how intensely a region absorbs the tracer - higher SUV = more aggressive/active cancer.
Findings Explained Region by Region
Brain
- Non-FDG avid ill-defined white matter opacities in bilateral frontal lobes - these areas do NOT take up the glucose tracer, meaning they are NOT cancer. They are likely old ischemic (stroke-like) changes. An MRI brain is recommended to clarify this.
Head & Neck
- No cancer found in the head, neck, or cervical lymph nodes. Clear.
Thorax (Chest) - KEY FINDINGS
| Finding | Size | SUVmax | Meaning |
|---|---|---|---|
| Entire left breast - ill-defined fat stranding | Whole breast | 2.59 (low grade) | Primary tumour - diffuse, non-measurable involvement |
| Skin thickening over left breast | - | - | Sign of inflammatory/locally advanced disease |
| Left axillary lymph nodes (multiple) | Largest: 3.7 × 2.5 cm | 11.55 (very high) | Confirmed metastatic spread to axilla |
| Left retropectoral nodes | Present | Elevated | Metastatic |
| Left supraclavicular nodes (few) | Largest: 1 × 0.8 cm | 3.74 | Metastatic (low-grade FDG avid) |
| Prevascular mediastinal nodes (few tiny) | Largest: 0.8 × 0.6 cm | Not FDG avid | Indeterminate - likely reactive, not metastatic |
| Solitary nodule, right lower lobe (superior segment) | 0.5 × 0.6 cm | Not FDG avid | Indeterminate - could be benign (old infection, granuloma) but needs follow-up |
The SUVmax of 11.55 in the axillary nodes is significantly elevated, indicating highly active metastatic disease.
Abdomen & Pelvis
- Completely clear - liver, pancreas, spleen, kidneys, adrenals, bowel, and peritoneum show no metastatic disease.
Skeletal System
- No bone metastases detected.
Final Impression (Summary by the Radiologist)
The scan confirms carcinoma of left breast with regional metastatic spread as follows:
- Diffuse, non-measurable primary tumour in the left breast with skin thickening
- Metabolically active (metastatic) left axillary lymph nodes - confirmed spread
- Metabolically active (metastatic) left retropectoral lymph nodes
- Metastatic left supraclavicular lymph nodes (low-grade activity)
- Indeterminate mediastinal prevascular nodes - not clearly metastatic
- Highly suspicious right lung nodule (0.5 × 0.6 cm, superior segment of right lower lobe) - not metabolically active on PET but morphologically suspicious; requires tissue biopsy or CT follow-up
Clinical Staging (TNM - AJCC 8th Edition)
Based on PET-CT findings:
| Component | Finding | Stage |
|---|---|---|
| T (Tumour) | Diffuse breast involvement with skin thickening | cT4 (locally advanced - skin involvement) |
| N (Nodes) | Left axillary + retropectoral + supraclavicular nodes | cN3 (supraclavicular node = N3c) |
| M (Metastasis) | No confirmed distant organ metastasis; lung nodule indeterminate | cM0 (or cM1 if lung confirmed) |
This places her at clinical Stage IIIC (cT4, cN3, cM0) at minimum. If the lung nodule is confirmed as a metastasis, it would be upgraded to Stage IV (cM1).
The overall staging and prognosis also critically depend on the ER/PR/HER2 receptor status and biopsy/histology results, which are not included in this PET-CT report.
Prognosis
The prognosis in this case depends on several factors. Here is a realistic breakdown:
Factors Suggesting Locally Advanced Disease (Stage IIIC)
- Supraclavicular node involvement (N3c) is a marker of advanced locoregional disease
- Skin thickening suggests possible inflammatory breast cancer component
- High SUVmax of 11.55 in axillary nodes indicates aggressive tumour biology
- Diffuse breast involvement (not a single discrete tumour mass)
Positive Prognostic Factors in This Case
- No bone metastases detected
- No liver, lung (confirmed), or abdominal organ metastases
- Staging as IIIC (rather than IV) still carries curative intent with multimodal treatment
5-Year Survival Reference (AJCC data)
| Stage | 5-Year Relative Survival |
|---|---|
| Stage IIIC | ~40-50% (anatomic) |
| Stage IV (if lung confirmed) | ~28% (but improving with modern therapies) |
These are population-based statistics. Individual prognosis is significantly modified by ER/PR status, HER2 status, age, performance status, and response to neoadjuvant chemotherapy. HER2-positive or hormone receptor-positive tumours carry considerably better outcomes with targeted therapies.
Recommended Next Steps
- Tissue biopsy of the primary breast tumour and/or axillary node - for histology, grade, ER/PR/HER2 receptor status, Ki-67 proliferation index
- CT-guided biopsy or PET-CT follow-up of the right lower lobe lung nodule to determine if it is benign or metastatic
- MRI brain - as recommended in the report, to evaluate the frontal lobe white matter opacities (likely old ischaemic, but must be excluded as metastases)
- Oncology multidisciplinary team (MDT) review - involving medical oncologist, surgical oncologist, radiation oncologist
- Neoadjuvant chemotherapy is typically the first treatment for locally advanced/Stage IIIC breast cancer - this is done before surgery to shrink the tumour and assess response
- If HER2-positive: add trastuzumab (Herceptin) to neoadjuvant regimen
- If hormone receptor-positive: plan for endocrine therapy post-treatment
Key Takeaway
This PET-CT confirms locally advanced left breast carcinoma (at minimum Stage IIIC) with metabolically active metastatic left axillary, retropectoral, and supraclavicular lymph nodes. There is no confirmed distant organ spread at this time, which is important - treatment remains potentially curative. The treatment team will design a comprehensive plan once the biopsy receptor status is known.
⚠️ Important: This analysis is for educational purposes. All treatment decisions must be made by the treating oncology team at the Cancer Centers of America who have access to the full clinical picture, biopsy results, and patient history.
This is a shared conversation. Sign in to Orris to start your own chat.